Equities analysts expect Amedisys Inc (NASDAQ:AMED) to report sales of $396.66 million for the current fiscal quarter, Zacks reports. Six analysts have made estimates for Amedisys’ earnings, with estimates ranging from $392.50 million to $403.67 million. Amedisys posted sales of $370.46 million during the same quarter last year, which suggests a positive year over year growth rate of 7.1%. The business is scheduled to report its next quarterly earnings results on Tuesday, May 1st.
On average, analysts expect that Amedisys will report full year sales of $396.66 million for the current year, with estimates ranging from $1.61 billion to $1.64 billion. For the next year, analysts expect that the company will post sales of $1.73 billion per share, with estimates ranging from $1.68 billion to $1.76 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Amedisys.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, February 27th. The health services provider reported $0.56 EPS for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.02). Amedisys had a net margin of 1.98% and a return on equity of 15.14%. The firm had revenue of $404.24 million during the quarter, compared to the consensus estimate of $394.96 million. During the same period in the prior year, the business earned $0.44 EPS.
A number of equities analysts have recently commented on the stock. BidaskClub lowered shares of Amedisys from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Jefferies Group set a $70.00 price target on shares of Amedisys and gave the company a “buy” rating in a research report on Wednesday, February 28th. Oppenheimer boosted their target price on shares of Amedisys from $68.00 to $63.00 and gave the stock an “outperform” rating in a research report on Thursday, March 1st. Zacks Investment Research raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research report on Tuesday, March 6th. Finally, TheStreet lowered shares of Amedisys from a “b” rating to a “c+” rating in a research report on Wednesday, February 28th. Five investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $63.18.
A number of hedge funds have recently made changes to their positions in AMED. Point72 Asset Management L.P. increased its position in Amedisys by 337.0% during the third quarter. Point72 Asset Management L.P. now owns 474,044 shares of the health services provider’s stock worth $26,528,000 after acquiring an additional 674,044 shares during the period. Millennium Management LLC boosted its stake in Amedisys by 58.2% during the fourth quarter. Millennium Management LLC now owns 1,048,423 shares of the health services provider’s stock worth $55,262,000 after buying an additional 385,734 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Amedisys by 29.7% during the third quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock worth $83,048,000 after buying an additional 339,825 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Amedisys during the fourth quarter worth $8,417,000. Finally, Eaton Vance Management boosted its stake in Amedisys by 67.2% during the fourth quarter. Eaton Vance Management now owns 338,488 shares of the health services provider’s stock worth $17,842,000 after buying an additional 136,001 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.
Amedisys (NASDAQ:AMED) traded down $0.03 during trading hours on Friday, hitting $61.40. 124,962 shares of the stock were exchanged, compared to its average volume of 324,408. Amedisys has a 12 month low of $45.60 and a 12 month high of $65.91. The company has a market capitalization of $2,088.70, a price-to-earnings ratio of 69.77, a price-to-earnings-growth ratio of 1.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.45 and a current ratio of 1.45.
WARNING: “$396.66 Million in Sales Expected for Amedisys Inc (AMED) This Quarter” was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.thelincolnianonline.com/2018/03/22/396-66-million-in-sales-expected-for-amedisys-inc-amed-this-quarter.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.